Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;9(1):63-88.
doi: 10.1177/2042098617744161. Epub 2017 Dec 13.

Naloxone dosage for opioid reversal: current evidence and clinical implications

Affiliations
Review

Naloxone dosage for opioid reversal: current evidence and clinical implications

Rachael Rzasa Lynn et al. Ther Adv Drug Saf. 2018 Jan.

Abstract

Opioid-related mortality is a growing problem in the United States, and in 2015 there were over 33,000 opioid-related deaths. To combat this mortality trend, naloxone is increasingly being utilized in a pre-hospital setting by emergency personnel and prescribed to laypersons for out-of-hospital administration. With increased utilization of naloxone there has been a subsequent reduction in mortality following an opioid overdose. Reversal of opioid toxicity may precipitate an opioid-withdrawal syndrome. At the same time, there is a risk of inadequate response or re-narcotization after the administration of a single dose of naloxone in patients who have taken large doses or long-acting opioid formulations, as the duration of effect of naloxone is shorter than that of many opioid agonists. As out-of-hospital use of this medication is growing, so too is concern about effective but safe dosing.

Keywords: harm reduction; naloxone; opioid overdose; route of administrations.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

    1. Centers for Disease Control and Prevention. Injury prevention and control: opioid overdose, www.cdc.gov/drugoverdose/data/statedeaths.html (2016, accessed 1 October 2017).
    1. Wheeler E, Jones TS, Gilbert MK, et al. Opioid overdose prevention programs providing naloxone to laypersons: United States, 2014. Morb Mortal Wkly Rep 2015; 64: 631–635. - PMC - PubMed
    1. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014; 8: 153–163. - PubMed
    1. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 2016; 111: 1177–1187. - PMC - PubMed
    1. Jasinski DR, Martin WR, Haertzen CA. The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther 1967; 157: 420–426. - PubMed